|Baroma Accountable Care||Member Title/ Position||ACO Participant TIN Legal Business Name|
|Gilda M De la Calle||MD/Member||Gilda De La Calle MD PA|
|Jose Manuel Armas||MD/Member||N/A|
|Javier Perez||MD/Member||Javier Perez MD PA|
|Rheinchard Reyes||MD/Co-Chair||Rheinchard Reyes MD PA|
|Gladys Alonso||MD/Member||Gladys Y. Alonso MD PA|
|Carlos Iglesias||MD/Member||Carlos Iglesias MD PA|
|Cathy F. Bowers||Consumer Advocate||N/A|
|Rene J Valverde||President at Baroma ACO|
|Janette Rojas||Compliance Officer at Baroma ACO|
|Dr. Eduardo Alarcon||Chairman/Medical Director at Baroma ACO|
|Kirenia Mijares||Clinical Improvement Officer at Baroma ACO|
|Dr. Maria Labarga||Chief Medical Officer|
|Clinical/Quality||Eduardo Alarcon; N/A||Rheinchard Reyes MD; Rheinchard Reyes MD PA|
|Marcelo Bendix; N/A||Javier Perez MD; Javier Perez MD PA|
|Vladimir Diaz; N/A.||Jorge Perez; N/A|
As a Next Generation ACO, Baroma ACO posts quality performance results each year. The next results will be posted in 2017
On December 9, 2015, the Secretary of the Department of Health & Human Services issued waivers of certain federal fraud and abuse laws in its Notice of Waiver of Certain Fraud and Abuse Laws in Connection with the Next Generation ACO Model, including the Next Generation ACO Participation Waiver. This disclosure is intended to qualify the investment by HCA, Inc. and its affiliates, through hInsight-BMA Holdings, LLC, into the parent company of Baroma Accountable Care, LLC (the “Investment”) for waiver protection under the Next Generation ACO Participation Waiver. The governing bodies of Baroma Accountable Care, LLC and its parent have duly authorized and made a bona fide determination that the Investment will assist in the development of the infrastructure of the Baroma Accountable Care, LLC ACO and further the coordination of care to Medicare beneficiaries and that such investment is reasonably related to the purposes and goals of the Next Generation ACO Model.
This disclosure is intended to provide public notice of the following arrangement with Quest Diagnostics as required under the Next Generation ACO Participation Waiver. The governing bodies of Baroma Accountable Care, LLC ACO have duly authorized and made a bona determination to collaborate with Quest Diagnostics, to provide enhanced laboratory services to Medicare Beneficiaries, and to further create an opportunity to improve healthcare and cost outcomes. Quest Diagnostics will assist in the development of the infrastructure of the ACO and further the coordination of care to Medicare beneficiaries and that such investment is reasonable related to the purposes and goals of the Next Generation ACO Model.
The ACO has no joint ventures between or among the ACO and any of its Participants and Preferred Providers.